Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Appendix 3B: New issue announcement, application for quotation of additional securities and agreement

180316_Appendix 3B and 3Y Notice

Recent Articles

November 1, Top 20 Shareholders
November 1, 2021
October 18, Canine Trial Update
October 18, 2021
October 1, Entitlement Options Issue Prospectus
October 1, 2021
October 1, Pro-Rata Non-Renounceable Entitlement Options Offer
October 1, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @PharmAust·

$PAA/@PharmAust has signed agreements with NZ-based Veterinary Specialists Auckland and Intuit Regulatory, to expand its canine Phase 2b lymphoma studies into the country ahead of the upcoming Phase 3 trial.

https://stockhead.com.au/health/pharmaust-expands-studies-in-nz-one-step-closer-towards-a-phase-3-trial-for-canine-cancer/

Reply on Twitter 1461470526476455941 Retweet on Twitter 14614705264764559413 Like on Twitter 146147052647645594110 Twitter 1461470526476455941

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions